/AI%20(artificial%20intelligence)/Artificial%20Intelligence%20technology%20concept%20by%20NicoEINino%20via%20Shutterstock.jpg)
Artificial intelligence (AI) has been the market’s favorite catalyst over the past year, fueling rallies across everything from chipmakers to cloud software stocks. But one of the more surprising success stories has come from healthcare, a sector not usually known for flashy AI-driven growth. That’s where Tempus AI (TEM) enters the picture. Going public just last year, Tempus is already experiencing sharp revenue gains and notable improvements in the bottom line, unlike the typical biotech IPOs that often hit the market with little revenue and long development timelines.
The company leverages one of the world’s largest multimodal data libraries to power AI tools that help physicians deliver personalized treatments while accelerating drug discovery. And investors are certainly taking notice, sending TEM shares soaring triple digits in 2025. That being said, does this AI-driven healthcare innovator still have more room to run?
